The partnership focuses on advancing oligonucleotide modalities, specifically antisense oligonucleotides and small interfering RNA. Grünenthal aims to refine the design and targeted delivery of these therapies to address complex conditions, including pain, epilepsy, and neurodegenerative disorders. By integrating its research with the cluster’s expertise, the company seeks to bridge the gap between academic science and patient-focused therapeutic outcomes.
In section Releases
Grünenthal Joins Munich Nucleic Acid Therapeutics Cluster
Aachen-based pharmaceutical firm Grünenthal has officially partnered with the Cluster for Nucleic Acid Therapeutics Munich, a move designed to accelerate the development of next-generation genetic medicines. The collaboration links the company’s internal drug discovery research with a network of top-tier academic institutions and biotech innovators across Germany.
Uli Brödl, Chief Scientific Officer at Grünenthal, noted that the initiative connects the company with experts dedicated to solving significant medical challenges. The cluster, supported by the Federal Ministry of Research, Technology and Space, includes major participants such as the Ludwig-Maximilians-Universität Munich, the Technical University of Munich, and the Helmholtz Centre Munich. This network serves as a hub for 14 companies and various research institutions, providing a foundation for scientific breakthroughs in nucleic acid chemistry and pharmacology.
Comments (0)
No comments yet. Be the first!